CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Capital Advisors Inc. OK

Capital Advisors Inc. OK boosted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 8.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 300,589 shares of the company's stock after buying an additional 22,583 shares during the period. Capital Advisors Inc. OK owned 0.35% of CRISPR Therapeutics worth $14,122,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in CRISPR Therapeutics by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 1,590,651 shares of the company's stock worth $99,575,000 after acquiring an additional 51,926 shares during the last quarter. SeaCrest Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics during the 1st quarter worth approximately $229,000. Principal Financial Group Inc. purchased a new stake in shares of CRISPR Therapeutics in the first quarter valued at approximately $2,758,000. Van ECK Associates Corp increased its holdings in shares of CRISPR Therapeutics by 6.0% in the first quarter. Van ECK Associates Corp now owns 71,944 shares of the company's stock valued at $4,904,000 after purchasing an additional 4,103 shares during the last quarter. Finally, Private Advisor Group LLC lifted its position in CRISPR Therapeutics by 51.8% during the first quarter. Private Advisor Group LLC now owns 13,551 shares of the company's stock worth $923,000 after buying an additional 4,625 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Stock Performance

Shares of CRSP traded up $4.37 during midday trading on Friday, hitting $50.76. The company had a trading volume of 2,263,380 shares, compared to its average volume of 1,447,851. CRISPR Therapeutics AG has a 1 year low of $43.42 and a 1 year high of $91.10. The firm has a market capitalization of $4.32 billion, a P/E ratio of -15.72 and a beta of 1.68. The company's 50-day simple moving average is $47.15 and its 200-day simple moving average is $52.38.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. CRISPR Therapeutics's quarterly revenue was down 99.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.98) EPS. Equities analysts predict that CRISPR Therapeutics AG will post -5.57 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Samarth Kulkarni sold 4,293 shares of the firm's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the company's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on CRSP shares. Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They set a "buy" rating and a $90.00 price target on the stock. Stifel Nicolaus decreased their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a "hold" rating on the stock in a report on Tuesday, August 6th. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a research note on Tuesday. Finally, Royal Bank of Canada decreased their price target on CRISPR Therapeutics from $60.00 to $53.00 and set a "sector perform" rating on the stock in a research note on Friday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $75.19.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.